Hennion & Walsh Asset Management Inc. Sells 17,560 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Hennion & Walsh Asset Management Inc. reduced its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 15.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 98,294 shares of the company’s stock after selling 17,560 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.19% of Mirum Pharmaceuticals worth $7,764,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Comerica Bank grew its position in shares of Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares during the period. AQR Capital Management LLC lifted its position in Mirum Pharmaceuticals by 307.3% during the first quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock valued at $2,211,000 after purchasing an additional 37,028 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Mirum Pharmaceuticals by 7.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock valued at $1,176,000 after purchasing an additional 1,720 shares in the last quarter. Caxton Associates LLP bought a new stake in Mirum Pharmaceuticals during the first quarter valued at about $217,000. Finally, Empowered Funds LLC grew its holdings in Mirum Pharmaceuticals by 15.4% during the first quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock valued at $1,729,000 after purchasing an additional 5,120 shares during the period.

Analysts Set New Price Targets

Several research firms have recently commented on MIRM. Evercore set a $126.00 price objective on Mirum Pharmaceuticals in a research note on Wednesday, March 4th. Robert W. Baird lifted their target price on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $130.00 target price on shares of Mirum Pharmaceuticals in a research report on Monday, December 8th. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. Finally, Royal Bank Of Canada cut their price target on Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating for the company in a report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Mirum Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $117.67.

Insider Activity at Mirum Pharmaceuticals

In related news, COO Peter Radovich sold 16,515 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $1,519,049.70. Following the sale, the chief operating officer owned 40,272 shares in the company, valued at approximately $3,704,218.56. This represents a 29.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Christopher Peetz sold 40,985 shares of Mirum Pharmaceuticals stock in a transaction on Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $3,769,800.30. Following the transaction, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at $17,872,541.82. The trade was a 17.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 121,942 shares of company stock worth $11,416,645 in the last ninety days. Corporate insiders own 14.36% of the company’s stock.

Mirum Pharmaceuticals Stock Performance

MIRM opened at $88.44 on Monday. The stock has a 50-day moving average of $96.36 and a 200 day moving average of $81.80. The company has a current ratio of 2.67, a quick ratio of 2.55 and a debt-to-equity ratio of 0.98. Mirum Pharmaceuticals, Inc. has a 12 month low of $36.88 and a 12 month high of $109.28. The firm has a market cap of $5.34 billion, a P/E ratio of -184.25 and a beta of 0.52.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). The company had revenue of $148.93 million for the quarter, compared to analysts’ expectations of $141.78 million. Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The company’s revenue for the quarter was up 49.8% on a year-over-year basis. During the same quarter last year, the company earned $1.00 earnings per share. As a group, research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.